← All indications
Scleroderma, Localized
A term used to describe a variety of localized asymmetrical SKIN thickening that is similar to those of SYSTEMIC SCLERODERMA but without the disease features in the multiple internal organs and BLOOD VESSELS. Lesions may be characterized as patches or plaques (morphea), bands (linear), or nodules.
Drugs by status
Phase 4 trials (1)
Phase 3 trials (1)
Phase 2 trials (5)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (17)
- 3M
- Allergan
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Arizona
- University of Pittsburgh
- Johns Hopkins University
- Postgraduate Institute of Medical Education and Research
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- University of Toronto
- University of Alberta
- University of Colorado, Denver
- University of Lille
- University of Texas at Houston
- India Army
- University of Sao Paulo
- Institute of Post Graduate Medical Education & Research
Organization Involved with Phase 2 Indications (39)
- Regeneron
- Actelion
- Celgene
- Bristol-Myers Squibb
- United Therapeutics
- Roche
- Genentech
- Pfizer
- Novartis
- Bayer
- Cumberland Pharmaceuticals
- Fibrocell Technologies, Inc.
- Medical Research Council
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Boston University
- University of London
- Duke University
- Georgetown University
- Northwestern University
- Stanford University
- University of Michigan
- University of Tehran
- University of Tennessee
- University of Bordeaux
- Wayne State University
- University of California, Los Angeles
- University of Cologne
- Vanderbilt University
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- +9 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (2)